CARGIRETA 10 (GLP-1 + GIP + GCGR)

CARGIRETA 10mg – Innovative peptide with synergistic action of GIP and glucagon

Product description

CARGIRETA 10mg is a modern biactive peptide, designed to simultaneously affect GIP (glucose-dependent insulinotropic peptide) and glucagon receptors. This combination opens up new possibilities in research on metabolism regulation, body weight control and optimization of the body's energy management.

This peptide is at the center of scientific interest as a potential future therapy for obesity and metabolic disorders – it works comprehensively, combining anabolic and lipolytic effects.

Potential effects (based on preclinical and clinical studies):

• Reduction of body weight and fat tissue while maintaining lean body mass
• Reduced appetite and prolonged feeling of satiety
• Improved insulin sensitivity and glycemic control
• Increased energy expenditure by stimulating glucagon receptors
• Support for the treatment of metabolic syndrome and type 1 diabetes

Application

The product is intended for research and analytical purposes only. It can be used in laboratory conditions to test new classes of anti-obesity and metabolic drugs.

Additional information

• Name: CARGIRETA

• Active substance:
  – Cagrilintide – amylin analogue (affects the feeling of satiety, reduces appetite)
  – Retatrutide – GLP-1/GIP/GCGR triple agonist (multiple effects on metabolism, glucose control and body weight reduction)

• Active substance content: 10 mg
• Form: Lyophilisate for dissolution
• Purity: ≥ 98% (HPLC)
• Synonym: LY3437943
• Classification: Chemical reagent for laboratory use

⚠️ Warning:

The product is not intended for human consumption.

CARGIRETA 10mg is not a dietary supplement or a medicinal product. Classified as a chemical reagent, authorized for marketing in the EU. For use only by qualified personnel in laboratory conditions.